Eisai
Alzheimer's Drug Discovery Foundation, Pharma Firms Form Biobank Alliance
Roche, Shionogi, Janssen Pharmaceuticals, and Eisai will provide the charity with specimens from Alzheimer's disease patients who participated in clinical studies.
PGDx, Eisai to Develop Next-Generation Sequencing Biomarker Assay
The group will create a kitted next-generation sequencing tool that will help researchers and biopharma firms conduct biomarker discovery work on patient blood samples.
AmoyDx, Eisai Form CDx Development Alliance
Tokyo-based Eisai develops drugs primarily for the neurology and oncology markets, including treatments for Parkinson's disease and breast cancer.
Bristol-Myers Squibb, H3 Biomedicine Form Cancer Immunotherapy Alliance
H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.
Cancer Genetics Signs Biomarker Services Deal with H3 Biomedicine
Cancer Genetics will provide the services to support H3's development of H3B-8800, a Phase I small molecule-based blood cancer drug candidate.